Real-world data begin to emerge for the Jynneos vaccine in monkeypox outbreak 

[Photo by Artem Podrez from Pexels]

Until recently, CDC had warned that it remained uncertain how effective the Jynneos vaccine from Bavarian Nordic A/S (OMX:BAVA) and the ACAM2000 vaccine from Emergent BioSolutions (NYSE:EBS) were at guarding against the current monkeypox outbreak. 

The CDC, however, has begun to release data related to the former vaccine. The agency found unvaccinated patients were approximately 14 times more likely to become infected with the virus based on early real-world effectiveness data. 

In the week of August 28, monkeypox incidence was 230 per 100,000 for unvaccinated individuals. Among those who received at least one dose of the Jynneos vaccine in the same period, 15 per 100,000 became infected. 

Although the U.S. government has made the ACAM2000 vaccine available for use against monkeypox, it remains unclear how protective it is in the current outbreak. 


Read more
  • 0

Jynneos vaccine: The best weapon against monkeypox?

[Image courtesy of HHS]

Over the past few months, healthcare leaders have been working on identifying vaccines to prevent the spread of monkeypox. One such development is the use of Bavarian Nordic’s (OMX:BAVA) Jynneos vaccine for the prevention and treatment of the fast-spreading disease.

The Jynneos vaccine won approval in the U.S. in 2019 for the prevention of monkeypox and smallpox. The vaccine is made with weakened vaccinia virus. The vaccine is indicated to help protect people against monkeypox. Specifically, it is intended to be given before exposure to the virus or reduce the risk of infection if given within four days after exposure. In addition, FDA has authorized its use to cut the risk of serious illness if given within 14 days after exposure.

The FDA approved the two-dose Jynneos vaccine in 2019 for people ages 18 and older with a high monkeypox or smallpox exposure risk.

Jynneos is no…

Read more
  • 0